The week in health tech, explained in plain English.Get the free newsletter →
November 18, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Government

Mark Cuban's Cost Plus to Develop US-Made Ibogaine for HHS

Mark Cuban Cost Plus Drug Co. will lead research teams laying the groundwork for a domestically manufactured ibogaine product, part of a Department of Health and Human Services effort to develop the psychedelic as a potential treatment for post-traumatic stress disorder and other serious mental illnesses, according to Becker's Hospital Review. HHS committed up to $4.9 million to the work, with veterans a central focus.

Ibogaine, a psychoactive compound derived from the African iboga plant, is not approved in the US and carries known cardiac risks. The federal interest signals growing willingness to study psychedelics as options for conditions that respond poorly to existing drugs. Building a domestic supply chain also fits a broader government push to onshore pharmaceutical manufacturing.

For Cost Plus, known for low-cost generic drugs, the project expands its role into early-stage drug development alongside the federal government. Any approved product remains years away, but the funding marks a concrete step toward bringing a controversial therapy into regulated research.

More in Government

Government

US Loses Measles Elimination Status After a Year of Spread

Global health authorities say the US has lost its measles elimination status after the disease spread continuously for over a year, ending a 25-year milestone.

Why it matters: Losing measles elimination status signals that a highly contagious, vaccine-preventable disease is again circulating freely in the U.S., threatening public health gains.

Government

Democrats Float 'Medicare for Kids' Ahead of 2026 Midterms

Democrats are floating a narrower "Medicare for Kids" proposal alongside the broader Medicare for All push as healthcare shapes the 2026 midterm debate.

Why it matters: The direction of Democratic healthcare policy could reshape coverage, reimbursement, and payer dynamics across the industry depending on 2026 election outcomes.